Exosomes and the Emerging field of exosome-based gene therapy

Current Gene Therapy

Volumn 12, Issue 4, 2012, Pages 262-274

  O'Loughlin, Aisling J ^a   Woffindale, Caroline A ^a   Wood, Matthew J A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Exosome; Gene delivery; Gene therapy; Nanomedicine; RNAi; Stem cells; Vector

Indexed keywords

MICRORNA; NANOCARRIER; NUCLEIC ACID; OLIGONUCLEOTIDE;

ARTICLE; CARDIOVASCULAR DISEASE; CELL COMMUNICATION; CELL ISOLATION; CELL THERAPY; CELL TRANSPORT; DRUG DELIVERY SYSTEM; ENCAPSULATION; EXOSOME; GENE DELIVERY SYSTEM; GENE THERAPY; HUMAN; INFLAMMATORY DISEASE; MEMBRANE VESICLE; NANOTECHNOLOGY; NEOPLASM; NEUROLOGIC DISEASE; RNA INTERFERENCE; TARGET CELL;

BLOOD-BRAIN BARRIER; CELL COMMUNICATION; DRUG DELIVERY SYSTEMS; EMBRYONIC STEM CELLS; EXOSOMES; GENETIC THERAPY; HUMANS; MICRORNAS; NANOTECHNOLOGY; RNA INTERFERENCE;

EID: 84864539550     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652312802083594     Document Type: Article

References (113)

1. Conde-Vancells J, Rodriguez-Suarez E, Embade N, et al. Characterization and comprehensive proteome profiling of exosomes secreted by hepatocytes. J Proteome Res 2008; 7[12]: 5157-66.
2. Stoorvogel W, Strous GJ, Geuze HJ, Oorschot V, Schwartz AL. Late endosomes derive from early endosomes by maturation. Cell 1991; 65[3]: 417-27.
3. Futter CE, Collinson LM, Backer JM, Hopkins CR. Human VPS34 is required for internal vesicle formation within multivesicular endosomes. J Cell Biol 2001; 155[7]: 1251-64.
4. Zakharova L, Svetlova M, Fomina AF. T cell exosomes induce cholesterol accumulation in human monocytes via phosphatidylserine receptor. J Cell Physiol 2007; 212[1]: 174-81.
5. Simpson RJ, Jensen SS, Lim JWE. Proteomic profiling of exosomes: current perspectives. Proteomics 2008; 8[19]: 4083-99.
6. Mathivanan S, Lim JWE, Tauro BJ, Ji H, Moritz RL, Simpson RJ. Proteomics analysis of A33 immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-specific protein signature. Mol Cell Proteomics 2010; 9[2]: 197-208.
7. Reggiori F, Pelham HR. Sorting of proteins into multivesicular bodies: ubiquitin-dependent and-independent targeting. EMBO J 2001; 20[18]: 5176-86.
8. Trajkovic K, Hsu C, Chiantia S, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 2008; 319[5867]: 1244-7.
9. Simpson RJ, Lim JW, Moritz RL, Mathivanan S. Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics 2009; 6[3]: 267-83.
10. Morelli AE, Larregina AT, Shufesky WJ, et al. Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood 2004; 104[10]: 3257-66.
11. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9[6]: 654-9.
12. Gibbings DJ, Ciaudo C, Erhardt M, Voinnet O. Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nat Cell Biol 2009; 11[9]: 1143-9.
13. Batagov AO, Kuznetsov, Vladimir A, Kurochkin, Igor V. Identification of nucleotide patterns enriched in secreted RNAs as putative cis-acting elements targeting them to exosome nano-vesicles. BMC Genomics 2011; 12[Suppl 3]: S18.
14. Bolukbasi MF, Mizrak A, Ozdener GB, et al. miR-1289 and "Zipcode"-like Sequence Enrich mRNAs in Microvesicles. Mol Ther Nucleic Acids 2012; 1[2]: e10.
15. Skog J, Würdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008; 10[12]: 1470-6.
16. Lotvall J, Valadi H. Cell to cell signalling via exosomes through esRNA. Cell Adh Migr 2007; 1[3]: 156-8.
17. Balaj L, Lessard R, Dai L, et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun 2011; 2: 180.
18. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116[2]: 281-97.
19. Baek D, Villén J, Shin C, et al. The impact of microRNAs on protein output. Nature 2008; 455[7209]: 64-71.
20. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466[7308]: 835-40.
21. Djuranovic S, Nahvi A, Green R. A parsimonious model for gene regulation by miRNAs. Science 2011; 331[6017]: 550-3.
22. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120[1]: 15-20.
23. Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008; 455[7209]: 58-63.
24. Available from: http://clinicaltrials.gov/ct2/results? term=siRNA&pg=1.
25. Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J 2011; 6[9]: 1130-46.
26. Armulik A, Genové G, Mäe M, et al. Pericytes regulate the bloodbrain barrier. Nature 2010; 468[7323]: 557-61.
27. Willis CL. Imaging in vivo astrocyte/endothelial cell interactions at the blood-brain barrier. Methods Mol Biol 2012; 814: 515-29.
28. Daneman R, Zhou L, Kebede AA, Barres BA. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature 2010; 468[7323]: 562-6.
29. Bell RD, Winkler EA, Sagare AP, et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 2010; 68[3]: 409-27.
30. Quaegebeur A, Segura I, Carmeliet P. Pericytes: blood-brain barrier safeguards against neurodegeneration? Neuron 2010; 68[3]: 321-3.
31. Araya R, Kudo M, Kawano M, et al. BMP signaling through BMPRIA in astrocytes is essential for proper cerebral angiogenesis and formation of the blood-brain-barrier. Mol Cell Neurosci 2008; 38[3]: 417-30.
32. Pardridge WM. Blood-brain barrier delivery. Drug Discov Today 2007; 12[1-2]: 54-61.
33. Schwerdt JI, Goya GF, Calatayud MP, Hereñú CB, Reggiani PC, Goya RG. Magnetic field-assisted gene delivery: achievements and therapeutic potential. Curr Gene Ther 2012; 12[2]: 116-26.
34. Andre FM, Mir LM. Nucleic acids electrotransfer in vivo: mechanisms and practical aspects. Curr Gene Ther 2010; 10[4]: 267-80.
35. Lee SW, Trapnell BC, Rade JJ, Virmani R, Dichek DA. In vivo adenoviral vector-mediated gene transfer into balloon-injured rat carotid arteries. Circ Res 1993; 73[5]: 797-807.
36. Byrnes AP, MacLaren RE, Charlton HM. Immunological instability of persistent adenovirus vectors in the brain: peripheral exposure to vector leads to renewed inflammation, reduced gene expression, and demyelination. J. Neurosci. 1996 May 1;16[9]:3045-55.
37. Amalfitano A, Hauser MA, Hu H, Serra D, Begy CR, Chamberlain JS. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol 1998; 72[2]: 926-33.
38. Gonzalez SC, McMenamin MM, Charlton HM, et al. Readministration of adenoviral gene delivery to dopamine neurons. Neuroreport 2007; 18[15]: 1609-14.
39. Marks WJ Jr, Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 2008; [5]: 400-8.
40. Kost TA, Condreay JP, Ames RS. Baculovirus gene delivery: a flexible assay development tool. Curr Gene Ther 2010; 10[3]: 168-73.
41. Mitchell AM, Nicolson SC, Warischalk JK, Samulski RJ. AAV's anatomy: roadmap for optimizing vectors for translational success. Curr Gene Ther. 2010 Oct;10 [5]:319-40.
42. Yi Y, Jong Noh M, Hee Lee K. Current Advances in Retroviral Gene Therapy. Curr Gene Ther 2011; 11[3]: 218-28.
43. Khare R, Chen CY, Weaver EA, Barry MA. Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther 2011; 4: 241-58.
44. Pannell D, Ellis J. Silencing of gene expression: implications for design of retrovirus vectors. Rev Med Virol 2001; 11[4]: 205-17.
45. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53[11]: 1617-23.
46. Paukner S, Kudela P, Kohl G, Schlapp T, Friedrichs S, Lubitz W. DNA-Loaded Bacterial Ghosts Efficiently Mediate Reporter Gene Transfer and Expression in Macrophages. Mol Ther 2005; 11[2]: 215-23.
47. Moreno M, Kramer MG, Yim L, Chabalgoity JA. Salmonella as live trojan horse for vaccine development and cancer gene therapy. Curr Gene Ther 2010; 10[1]: 56-76.
48. Geier MR, Trigg ME, Merril CR. Fate of bacteriophage lambda in non-immune germ-free mice. Nature 1973; 246[5430]: 221-3.
49. Larocca D, Witte A, Johnson W, Pierce GF, Baird A. Targeting bacteriophage to mammalian cell surface receptors for gene delivery. Hum Gene Ther 1998; 9[16]: 2393-9.
50. Larocca D, Jensen-Pergakes K, Burg MA, Baird A. Receptortargeted gene delivery using multivalent phagemid particles. Mol Ther 2001; 3[4]: 476-84.
51. Jepson CD, March JB. Bacteriophage lambda is a highly stable DNA vaccine delivery vehicle. Vaccine 2004; 22[19]: 2413-9.
52. Li S, Tseng WC, Stolz DB, Wu SP, Watkins SC, Huang L. Dynamic changes in the characteristics of cationic lipidic vectors after exposure to mouse serum: implications for intravenous lipofection. Gene Ther 1999; 6[4]: 585-94.
53. Zimmermann TS, Lee ACH, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006; 441[7089]: 111-4.
54. Schaffert D, Wagner E. Gene therapy progress and prospects: synthetic polymer-based systems. Gene Therapy 2008; 15[16]: 1131-8.
55. Semple SC, Akinc A, Chen J, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010; 28[2]: 172-6.
56. Khurana B, Goyal AK, Budhiraja A, Arora D, Vyas SP. siRNA delivery using nanocarriers-an efficient tool for gene silencing. Curr Gene Ther 2010; 10[2]: 139-55.
57. Tiera MJ, Shi Q, Winnik FM, Fernandes JC. Polycation-based gene therapy: current knowledge and new perspectives. Curr Gene Ther 2011; 11[4]: 288-306.
58. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJA. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 2011; [4]: 341-5.
59. Alvarez-Erviti L, Seow Y, Schapira AH, et al. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis 2011; 42[3]: 360-7.
60. Kim S-H, Lechman ER, Bianco N, et al. Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J Immunol 2005; 174[10]: 6440-8.
61. Lai RC, Arslan F, Lee MM, Sze NSK, Choo A, Chen TS, et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res 2010; 4[3]: 214-22.
62. Kim SH, Bianco N, Menon R, et al. Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive. Mol Ther 2006; 13[2]: 289-300.
63. Record M, Subra C, Silvente-Poirot S, Poirot M. Exosomes as intercellular signalosomes and pharmacological effectors. Biochem Pharmacol 2011; 81[10]: 1171-82.
64. Subra C, Laulagnier K, Perret B, Record M. Exosome lipidomics unravels lipid sorting at the level of multivesicular bodies. Biochimie 2007; 89[2]: 205-12.
65. Akao Y, Iio A, Itoh T, et al. Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages. Mol Ther 2011; 19[2]: 395-9.
66. Zhang Y, Liu D, Chen X, Li J, Li L, Bian Z, et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell 2010; 39[1]: 133-44.
67. Flint PW, Li ZB, Lehar M, Saito K, Pai SI. Laryngeal muscle surface receptors identified using random phage library. Laryngoscope 2005; 115[11]: 1930-7.
68. Kumar P, Wu H, McBride JL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007; 448[7149]: 39-43.
69. Dominguez DI, De Strooper B, Annaert W. Secretases as therapeutic targets for the treatment of Alzheimer's disease. Amyloid 2001; 8[2]: 124-42.
70. Kao S-C, Krichevsky AM, Kosik KS, Tsai L-H. BACE1 suppression by RNA interference in primary cortical neurons. J Biol Chem 2004; 279[3]: 1942-9.
71. Pan Q, Ramakrishnaiah V, Henry S, et al. Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi). Gut 2011; doi:10.1136/gutjnl-2011-300449
72. Kim H-W, Cho K-J, Lee SK, Kim GW. Apoptosis signalregulating kinase 1 (Ask1) targeted small interfering RNA on ischemic neuronal cell death. Brain Res 2011; 1412: 73-8.
73. He Z, Ostrowski RP, Sun X, et al. CHOP Silencing Reduces Acute Brain Injury in the Rat Model of Subarachnoid Hemorrhage. Stroke 2012; 43[2]: 484-90
74. Junn E, Mouradian MM. MicroRNAs in neurodegenerative diseases and their therapeutic potential. Pharmacol Ther 2012; 133[2]: 142-50.
75. Hébert SS, Horré K, Nicolaï L, et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci U.S.A. 2008; 105[17]: 6415-20.
76. Wang W-X, Rajeev BW, Stromberg AJ, et al. The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci 2008; 28[5]: 1213-23.
77. Kim J, Inoue K, Ishii J, et al. A MicroRNA feedback circuit in midbrain dopamine neurons. Science 2007; 317[5842]: 1220-4.
78. Miñones-Moyano E, Porta S, Escaramís G, et al. MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum Mol Genet 2011; 20[15]: 3067-78.
79. Lee S-T, Chu K, Im W-S, et al. Altered microRNA regulation in Huntington's disease models. Exp Neurol 2011; 227[1]: 172-9.
80. Packer AN, Xing Y, Harper SQ, Jones L, Davidson BL. The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease. J Neurosci 2008; 28[53]: 14341-6.
81. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007; 4[9]: 721-6.
82. Bianco NR, Kim SH, Ruffner MA, Robbins PD. Therapeutic effect of exosomes from indoleamine 2,3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models. Arthritis Rheum 2009; 60[2]: 380-9.
83. Kim SH, Bianco NR, Shufesky WJ, Morelli AE, Robbins PD. Effective treatment of inflammatory disease models with exosomes derived from dendritic cells genetically modified to express IL-4. J Immunol 2007; 179[4]: 2242-9.
84. Zhuang X, Xiang X, Grizzle W, et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated antiinflammatory drugs from the nasal region to the brain. Mol Ther 2011; 19[10]: 1769-79.
85. Sun D, Zhuang X, Xiang X, et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther 2010; 18[9]: 1606-14.
86. Timmers L, Lim SK, Arslan F, et al. Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Research 2008; 1[2]: 129-37.
87. Chen TS, Arslan F, Yin Y, et al. Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs. J Transl Med 2011; 9: 47.
88. Zitvogel L, Regnault A, Lozier A, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cellderived exosomes. Nat Med 1998; 4[5]: 594-600.
89. Théry C, Duban L, Segura E, Véron P, Lantz O, Amigorena S. Indirect activation of naïve CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol 2002; 3[12]: 1156-62.
90. André F, Chaput N, Schartz NEC, et al. Exosomes as potent cellfree peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol 2004; 172[4]: 2126-36.
91. Chaput N, Schartz NEC, André F, et al. Exosomes as potent cellfree peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol 2004; 172[4]: 2137-46.
92. Wolfers J, Lozier A, Raposo G, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001; 7[3]: 297-303.
93. Morse MA, Garst J, Osada T, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 2005; 3[1]: 9.
94. Escudier B, Dorval T, Chaput N, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derivedexosomes: results of the first phase I clinical trial. J Transl Med 2005; 3[1]: 10.
95. Dai S, Wei D, Wu Z, et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther 2008; 16[4]: 782-90.
96. Yang Y, Xiu F, Cai Z, et al. Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells. J Cancer Res Clin Oncol 2007; 133[6]: 389-99.
97. Zhang Y, Luo C-L, He B-C, Zhang J-M, Cheng G, Wu X-H. Exosomes derived from IL-12-anchored renal cancer cells increase induction of specific antitumor response in vitro: a novel vaccine for renal cell carcinoma. Int J Oncol 2010; 36[1]: 133-40.
98. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10[10]: 704-14.
99. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435[7043]: 834-8.
100. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U.S.A. 2002; 99[24]: 15524-9.
101. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005; 120[5]: 635-47.
102. Yu F, Yao H, Zhu P, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007; 131[6]: 1109-23.
103. Tseng S-Y, Nishimoto KP, Silk KM, et al. Generation of immunogenic dendritic cells from human embryonic stem cells without serum and feeder cells. Regen Med 2009; 4[4]: 513-26.
104. Park I-H, Arora N, Huo H, et al. Disease-specific induced pluripotent stem cells. Cell 2008; 134[5]: 877-86.
105. Stengel G, Zahn R, Höök F. DNA-induced programmable fusion of phospholipid vesicles. J Am Chem Soc 2007; 129[31]: 9584-5.
106. Admyre C, Johansson SM, Qazi KR, et al. Exosomes with immune modulatory features are present in human breast milk. J Immunol 2007; 179[3]: 1969-78.
107. Yin H, Moulton HM, Betts C, et al. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet 2009; 18[22]: 4405-14.
108. Skriner K, Adolph K, Jungblut PR, Burmester GR. Association of citrullinated proteins with synovial exosomes. Arthritis Rheum 2006; 54[12]: 3809-14.
109. Nguyen DG, Booth A, Gould SJ, Hildreth JEK. Evidence that HIV budding in primary macrophages occurs through the exosome release pathway. J Biol Chem 2003; 278[52]: 52347-54.
110. Rajendran L, Honsho M, Zahn TR, et al. Alzheimer's disease betaamyloid peptides are released in association with exosomes. Proc Natl Acad Sci U.S.A. 2006; 103[30]: 11172-7.
111. Fevrier B, Vilette D, Archer F, et al. Cells release prions in association with exosomes. Proc Natl Acad Sci U.S.A. 2004; 101[26]: 9683-8.
112. De La Peña H, Madrigal JA, Rusakiewicz S, et al. Artificial exosomes as tools for basic and clinical immunology. J Immunol. Methods 2009; 344[2]: 121-32.
113. Martinez-Lostao L, García-Alvarez F, Basáñez G, et al. Liposomebound APO2L/TRAIL is an effective treatment in a rabbit model of rheumatoid arthritis. Arthritis Rheum 2010; 62[8]: 2272-82.